From: The state of the art of adeno-associated virus-based vectors in gene therapy
Category/Disease | Clinical trial | ||||
---|---|---|---|---|---|
 | Phase I O/C* | Phase I/II O/C | Phase II O/C | Phase III O/C | Total |
Infeccious | Â | Â | Â | Â | Â |
   HIV vaccine | 2/0 | 0/0 | 0/0 | 0/0 | 2 |
Cancer | Â | Â | Â | Â | Â |
   Malignant melanoma | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
   Prostate cancer | 0/1 | 2/1 | 0/0 | 4/0 | 8 |
   Hormone refractory prostate cancer | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
   Metastatic prostate cancer | 0/0 | 0/0 | 0/0 | 1/0 | 1 |
Genetic | Â | Â | Â | Â | Â |
   Lipoprotein lipase deficience | 0/0 | 1/0 | 0/0 | 0/0 | 1 |
   Haemophilia B | 1/2 | 0/0 | 0/0 | 0/0 | 3 |
   Early onset retinal degeneration | 3/0 | 0/0 | 0/0 | 0/0 | 3 |
   Cystic fibrosis | 2/3 | 1/1 | 0/2 | 0/0 | 9 |
   Muscular dystrophy | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
   Canavan disease | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
   Duchenne muscular dystrophy | 1/1 | 0/0 | 0/0 | 0/0 | 2 |
   Limb Girdle muscular dystrophy | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
   Amyotrophic lateral sclerosis | 1**/0 | 0/0 | 0/0 | 0/0 | 1 |
   Inherited autosomal recessive alpha-1-antitrypsin deficiency | 2/0 | 0/0 | 0/0 | 0/0 | 2 |
   Late infantile neuronal ceroid lipofuscinosis | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
Neurological | Â | Â | Â | Â | Â |
   Parkinson's disease | 1/1 | 0/0 | 1/0 | 0/0 | 3 |
   Alzheimer's disease | 0/0 | 0/1 | 0/0 | 0/0 | 1 |
   Epilepsy | 1/0 | 0/0 | 0/0 | 0/0 | 1 |
Cardiovascular | Â | Â | Â | Â | Â |
   Heart failure | 2/0 | 0/0 | 0/0 | 0/0 | 2 |
Others | Â | Â | Â | Â | Â |
   Rheumatoid arthritis | 2/0 | 0/0 | 0/0 | 0/0 | 2 |
TOTAL | 24/8 | 4/3 | 1/2 | 5/0 | 47 |